8-K: vTv Therapeutics Updates Investors on Phase 3 Diabetes Drug

vTv Therapeutics Inc. posted an updated investor presentation highlighting its lead asset, Cadisegliatin, in Phase 3 development for Type 1 Diabetes with topline data expected in 2H 2026.

Summary

• vTv Therapeutics Inc. (VTVT) has updated its investor presentation, focusing on Cadisegliatin, a late-stage asset in Phase 3 development for Type 1 Diabetes (T1D).
• Cadisegliatin has the potential to be the first oral adjunctive therapy for T1D in the U.S., addressing a significant unmet need where approximately 75% of T1D patients do not achieve recommended blood glucose levels.
• Topline Phase 3 CATT1 study data for Cadisegliatin is targeted for the second half of 2026.
• The company reported a strong balance sheet with $98.5 million in cash as of September 30, 2025, plus an additional $20.0 million received on February 2, 2026, providing financial runway past the CATT1 data readout.
• Cadisegliatin has received FDA Breakthrough Therapy Designation for the treatment of T1D and is supported by a global patent portfolio providing protection through 2041.
• Phase 2 SimpliciT1 trial data showed Cadisegliatin significantly reduced HbA1c by 0.36% (p<0.001) and symptomatic hypoglycemic episodes by 50% (p=0.04) compared to insulin alone, with no increased risk of ketoacidosis.
• The company also highlighted a deep pipeline of other clinical-stage assets in immunology/inflammation, metabolism, and oncology, including HPP737, Azeliragon, TTP273, and HPP971/HPP3033, which present opportunities for non-dilutive funding.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive update, primarily driven by the strong financial position providing runway past a key Phase 3 data readout and the significant unmet need Cadisegliatin addresses in Type 1 Diabetes. The FDA Breakthrough Designation further de-risks the lead asset.

Positives

• Cadisegliatin is a late-stage asset in Phase 3 development with the potential to be the first oral adjunctive therapy for Type 1 Diabetes in the U.S.
• Topline Phase 3 CATT1 data for Cadisegliatin is targeted for 2H 2026, providing a clear near-term catalyst.
• Cadisegliatin has received FDA Breakthrough Therapy Designation, indicating potential for expedited review and development.
• Phase 1/2 studies in over 500 participants support a favorable profile, demonstrating reduction in hypoglycemia and HbA1c.
• The company possesses a strong balance sheet with $98.5 million cash (as of 9/30/2025) and an additional $20.0 million received (on 2/2/2026), providing financial runway well past the CATT1 topline data readout.
• An experienced leadership team with a strong track record in metabolic diseases and diabetes leads the company.
• A deep pipeline of differentiated assets beyond Cadisegliatin (HPP737, Azeliragon, TTP273, HPP971/HPP3033) offers additional upside and potential for non-dilutive funding.

Risks

• Actual future operations, opportunities, product development processes and outcomes, clinical trial processes and outcomes, regulatory approval processes and outcomes, economic performance of products, fundraising activities, and financial performance may differ materially from forward-looking statements.
• Known and unknown risks and uncertainties, some of which may not be within the company's control, could impact future results.
• Undue reliance should not be placed on forward-looking statements, which speak only as of the date of the presentation.
• The safety and efficacy of pipeline candidates (HPP737, Azeliragon, TTP273, HPP971/HPP3033) have not been established, and there is no guarantee they will receive health authority approval or become commercially available.

Future Outlook

The company targets topline Phase 3 CATT1 data for Cadisegliatin in the second half of 2026. It anticipates advancing other pipeline assets, including Azeliragon (Phase 2 initiation in 2025) and TTP273 (Phase 2 ready), and expects potential non-dilutive funding from its broader portfolio. The global T1D population is projected to grow to 14.7 million by 2040.

Management Comments

• Committed to improving the lives of people with diabetes.
• Cadisegliatin has the potential to be the first oral adjunctive therapy for type 1 diabetes in the U.S.
• The company has a strong balance sheet providing runway well past the CATT1 topline data readout.
• Deep pipeline of differentiated assets presents opportunities for significant non-dilutive funding.

Industry Context

StockSavvy.ai notes that the diabetes market, particularly for Type 1 Diabetes, represents a significant unmet medical need, with approximately 75% of patients failing to achieve target HbA1c levels and no FDA-approved oral adjunctive therapies available. Cadisegliatin, if approved, would enter a market currently dominated by insulin and injectables, offering a novel oral option that could significantly improve patient adherence and outcomes by reducing hypoglycemia, a major limiting factor in glycemic management. The company's focus on a glucokinase activator positions it uniquely against existing and emerging GLP-1 agonists, which primarily target Type 2 Diabetes and obesity, by offering a distinct mechanism of action tailored for T1D.

Comparison to Industry Standards

• Cadisegliatin aims to be the first oral adjunctive therapy for Type 1 Diabetes in the U.S., a market segment that has seen no new oral approvals since insulin's discovery in 1921, setting a new standard.
• The Phase 2 SimpliciT1 trial results for Cadisegliatin, showing a 0.36% reduction in HbA1c and 50% fewer symptomatic hypoglycemic episodes, compare favorably to the challenges faced by current insulin-only regimens where hypoglycemia is a major limiting factor.
• Unlike many GLP-1 agonists (e.g., Ozempic, Wegovy from Novo Nordisk; Mounjaro, Zepbound from Eli Lilly) which are primarily injectables and often associated with gastrointestinal side effects, vTv's TTP273 (oral GLP-1 agonist) is highlighted for negligible observed GI side effects, potentially offering improved tolerability and convenience.
• The company's approach to T1D with a hepatoselective glucokinase activator (Cadisegliatin) is distinct from SGLT2 inhibitors (e.g., Jardiance, Farxiga) which have been explored as adjunctive therapies for T1D but carry risks of diabetic ketoacidosis (DKA); Cadisegliatin's insulin withdrawal study showed no increased risk of ketoacidosis.

Stakeholder Impact

• Shareholders: Potential for significant value creation if Cadisegliatin's Phase 3 trial is successful and gains regulatory approval, given the large unmet need and market opportunity. The strong cash position reduces immediate dilution risk.
• Patients with Type 1 Diabetes: Potential for a novel oral adjunctive therapy that could improve glycemic control and reduce life-threatening hypoglycemic events, significantly enhancing quality of life.
• Healthcare Providers: Introduction of a new treatment option for T1D that could simplify management and improve patient outcomes.
• Employees: Continued employment and potential growth opportunities within a company advancing late-stage clinical assets.

Next Steps

• Topline Phase 3 CATT1 data readout for Cadisegliatin targeted for 2H 2026.
• Continued development of HPP737, Azeliragon, TTP273, and HPP971/HPP3033 pipeline assets.
• Potential for non-dilutive funding from broader portfolio assets.

Key Dates

Recommendation

The company presents a compelling narrative with a lead asset in Phase 3 for a significant unmet medical need and a strong cash position to reach a key data readout. The FDA Breakthrough Designation is a strong positive. However, the 'hold' recommendation reflects the inherent high risk associated with clinical-stage biotechnology companies, particularly awaiting pivotal Phase 3 data. While the potential upside is substantial, the outcome of the CATT1 trial remains a binary event. Investors should await the topline data in 2H 2026 before making a more definitive investment decision, as success or failure will significantly impact the stock price.

Keywords

Type 1 Diabetes, Cadisegliatin, TTP399, Oral Adjunctive Therapy, Glucokinase Activator, Phase 3 Clinical Trial, FDA Breakthrough Designation, Hypoglycemia, HbA1c, Biotechnology, Pharmaceuticals, Metabolic Disease, Drug Development, VTVT